Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate

Current Hematologic Malignancy Reports

Volumn 2, Issue 1, 2007, Pages 43-46

  Silver, Richard T ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HYDROXYUREA; IMATINIB; PREDNISONE; RECOMBINANT ALPHA INTERFERON; VINCRISTINE;

ANEMIA; BONE PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DERMATOLOGY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INHIBITION; DRUG WITHDRAWAL; ERYTHROCYTOSIS; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER TOXICITY; MYELOFIBROSIS; NEURITIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; REVIEW; SEIZURE; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOSIS; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ADULT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; JANUS KINASE 2; MALE; MIDDLE AGED; PHLEBOTOMY; PIPERAZINES; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34250782027     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0006-2     Document Type: Review

References (26)

1. Berk PD, Goldberg JD, Donovan PB, et al.: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986, 23:132-143.
2. Weinfeld A, Swolin B, Westin J: Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994, 52:134-139.
3. Silver RT: Hydroxyurea and sickle cell crisis [letter]. N Engl J Med 1995, 333:1008.
4. Najean Y, Deschamps A, Driesch C, et al.: Acute leukemia and myelodysplasia in polycythemia vera. Cancer 1988, 61:89-95.
5. Najean Y, Driesch C, Rain JD: The very long-term course of polycythemia: a complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 1994, 86:233-235.
6. Najean Y, Mugnier P, Driesch C, et al.: Polycythemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Hematol 1987, 67:285-291.
7. Silver RT: A new treatment for polycythemia vera: recombinant interferon alpha. Blood 1990, 76:664-665.
8. Means RT, Krantz SB: Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991, 78:2564-2567.
9. Costello R, Lerza A, Cerruti D, et al.: The in vitro and in vivo effect of recombinant interferon on circulating haemapoietic progenitors in polycythaemia vera. Br J Haematol 1994, 87:621-623.
10. Chott A, Gisslinger H, Thiele J, et al.: Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphological study on bone marrow biopsies in chronic myeloproliferative disorders with excess thrombocytosis. Br J Haematol 1990, 74:10-16.
11. Sinzinger H, Linkesch W, Ludwig H, et al.: Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha. Prostaglandins 1990, 40:351-360.
12. Lin SL, Kikuchi T, Pledger WJ, et al.: Interferon inhibits the establishment of competence in Go/S-phase transition. Science 1986, 233:356-359.
13. Martyre MC, Nagdelenat H, Caldo F: Interferon gamma in vivo reverses the increased platelet levels of platelet-derived growth factors in transforming growth factor-b in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991, 77:431-435.
14. Silver RT: Interferon-a2b: a new treatment for polycythemia vera. Ann Intern Med 1993, 119:1091-1092.
15. Thomas DJ, du Boulay GH, Marshall J, et al.: Cerebral blood flow in polycythaemia. Lancet 1977, 2(8030):161-163.
16. Silver RT: Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006, 107:451-458.
17. Silver RT: Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003, 17:1186-1187.
18. Silver RT, Fruchtman S, Feldman E, et al.: Imatinib mesylate (Gleevec®) is effective in the treatment of polycythemia vera: A multi-institutional clinical trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 656. This exceptionally important abstract details the results of treating 32 patients with polycythemia vera with imatinib mesylate.
19. Feldman EJ, Spivak JL, Lee S, et al.: Imatinib mesylate is effective in the treatment of polycythemia vera: a multi-institutional clinical trial [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings) 2006, 24:6532.
20. Jones CM, Dickinson TM: Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003, 325:149-152.
21. Hasselbalch H: Imatinib mesylate in polycythemia vera. A heterogeneous response pattern but a consistent reduction in phlebotomy requirements [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 4747.
22. Hino M, Futami E, Okuno S, et al.: Possible selective effects of interferon α-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993, 66:161-162.
23. Messora C, BeQsi L, Vecchi A, et al.: Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha. Br J Haematol 1994, 86:402-404.
24. Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168.
25. Jones AV, Silver RT, Waghorn K, et al.: Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006, 107:3339-3341.
26. Kiladjian JJ, Cassinat B, Turlure P, et al.: High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 2006, 108:2037-2040.